Texas Moves Ahead With State-Led Ibogaine Clinical Trials As Search for Drug Partner Falls Short

Texas plans to move forward with state-led ibogaine clinical trials after an effort to find a pharmaceutical company partner did not produce a deal. The decision keeps momentum behind a closely watched research effort centered on the psychedelic compound, which some veterans and advocates believe could help treat addiction, trauma, and brain injuries.

The development matters in Houston and across Texas because the state has become a leading backer of ibogaine research. Lawmakers previously directed funding toward studying the substance, even though ibogaine remains illegal in the United States and has not been approved by the U.S. Food and Drug Administration for medical use.

Why Texas Is Launching Ibogaine Clinical Trials

State leaders had hoped a drug company would help carry the research forward. However, after that effort fell short, Texas officials chose to pursue the work through a state-supported path instead. The goal is to produce the kind of clinical evidence required for federal review and, eventually, possible drug development.

Ibogaine is a psychedelic derived from a West African shrub. Supporters say it has shown potential in early and anecdotal reports, especially for opioid use disorder, other forms of addiction, and neurological conditions. At the same time, researchers have warned that the drug carries serious safety risks, including cardiac complications, which is why formal clinical trials are considered essential.

Texas has drawn national attention for backing this area of research, in part because of interest from veterans seeking new treatment options. Advocates have argued that current therapies do not work for everyone, especially for people dealing with post-traumatic stress, traumatic brain injuries, or substance use disorders after military service.

What Happens Next

The next phase will involve organizing state-backed clinical testing and meeting the scientific and regulatory standards needed for credible results. That process is likely to take time, and researchers will need to address both efficacy and safety before ibogaine could move closer to wider medical use.

For Houston-area readers, the story reflects a broader Texas role in shaping emerging health research. While the trials are not a treatment rollout, they could influence future medical policy, investment, and care options tied to addiction recovery and veteran health.

The move also highlights how states can step in when private-sector interest is limited. In this case, Texas appears willing to fund and organize early-stage research itself rather than wait for a pharmaceutical company to lead the effort.

This article is a summary of reporting by The Texas Tribune. Read the full story here.